Somerville gene therapy company cutting nearly 100 jobs

Another restructuring is underway at bluebird bio Inc., this time with plans to lay off about 25% of the Somerville company’s workforce. 

Bluebird said Tuesday that the latest cuts are part of its plan to achieve quarterly cash flow break-even in the second half of 2025. Bluebird noted that the restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period.

WATCH ANYTIME FOR FREE

Stream NBC10 Boston news for free, 24/7, wherever you are.

More on this story from Boston Business Journal